Cannasouth (NZX:CBD): How is the Company’s research initiative progressing?

Highlights

• Cannasouth is undertaking crucial research initiatives to create innovative and next-generation medicinal cannabis products therapeutics.
• Its team is working on developing cost-effective extracts to ease neuropathic pain and treat other specific conditions.
• CBD’s R&D department is concentrating on identifying new molecules and compounds by using advanced technologies.

Cannasouth Limited (NZX:CBD), which is a famous medicinal cannabis company, aims to develop next-gen medicinal cannabinoid therapeutics for patients both domestically as well as internationally.

Do Read: CBD, GEO, MHM- 3 NZX penny stocks garnering investors’ attention

Based in Waikato, the Company boasts a world-class team of researchers and has set up advanced research labs, as well as cultivation and manufacturing facilities.

Source: © 2022 Kalkine Media® data source- EODHD/Others

Aiming at making affordable products by using high-tech scientific know-how

Of late, Cannasouth has undertaken numerous significant research initiatives with the help of the funding received from Callaghan Innovation.

Related Read: Which 3 NZX healthcare stocks can be considered in 2022?

Its R&D team is focused on developing simple and affordable tinctures and extracts with the aid of new technologies.

In this regard, the team is working on identifying new molecules and compounds from cannabis extracts using advanced scientific know-how. Moreover, CBD has collaborated with a university to create biological models to test cannabinoids for the improved management of neuropathic pain, as a significant chunk of the global population is suffering from it and needs such medications to cure or ease suffering.

Ensuring right pre-clinical data and patient cohort for successful clinical trials

Furthermore, as far as clinical trials are concerned, CBD is aiming for successful clinical trial outcomes by using pre-clinical data in the future and ensuring the right trial type, patient group and clinical endpoint.

This will help in getting the requisite product approval and, at the same time, would help in raising funds from agencies like Pharmac, etc., so as to reduce costs for the patients.

Completed commissioning of a cultivation facility

Cannasouth is optimistic about achieving key milestones in the coming months as it aims to enhance its business operations to deliver cost effectiveness to treat specific conditions for local and export markets.

One such significant milestone is the completion of the commissioning of a new state-of-the-art greenhouse and processing facility located in Waikato. The process comprised of an intensive program of testing and certifying high-tech equipment and control systems, thus ensuring the operation of a world-class cultivation facility.

Bottom Line

Cannasouth Limited is committed to producing and supplying top-class pharmaceutical-grade medicinal cannabis products to both its local as well as global prescribers as well as patients.

At the closing session on 10 February, Cannasouth traded flat at NZ$0.340.